Compare ProShares Ultra Semiconductors (USD) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra Semiconductors vs Viatris Inc — how do they compare? ProShares Ultra Semiconductors trades at $99.09 (market cap $2.94B), while Viatris Inc trades at $17.47 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 6.8× ProShares Ultra Semiconductors's market cap, and Viatris Inc pays a 2.75% dividend while ProShares Ultra Semiconductors pays none. Which is the better fit depends on your goals — on Pluang, investors hold ProShares Ultra Semiconductors for 29 Days and Viatris Inc for 57 Days on average.
| USD | VTRS | |
|---|---|---|
Market Cap | $2.94B | $20.03B |
Volume | 630,148 | 14,109,977 |
Sector | Leveraged / Inverse | Health |
52-Week High | $113.53 | $18.27 |
52-Week Low | $43.19 | $9.74 |
Typical Hold Time | 29 Days | 57 Days |
Enterprise Value | — | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
USD stock trades at $102.77, down 0.96% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong momentum indicators with ADX signaling trend strength, though RSI levels suggest potential overbought conditions. Recent corporate action includes a $0.13 dividend scheduled for September 2026. Support levels are established at $100-$102, with resistance at $103-$105.
The stock's technical strength contrasts with limited fundamental data availability. Investment opportunity lies in the bullish technical setup and dividend yield, while risks include potential overbought conditions and lack of current financial metrics. Investors should await updated financial reports for fundamental validation of the current price level.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal and strong recent earnings beats. The company shows improving operational cash flow of $2.32B in 2025 and positive revenue growth trends, though profitability remains challenged with negative net margins. Recent developments include FDA approval for WAKIX in Japan and consistent dividend payments, supporting the bullish analyst consensus with a $22.17 price target representing 27% upside potential.
The outlook remains cautiously optimistic with strong cash generation supporting shareholder returns, but investors face risks from persistent negative profitability and high debt levels. The stock offers value appeal with reasonable P/S and P/B ratios, though the elevated P/E ratio reflects current earnings challenges that need resolution for sustained re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ProShares Ultra Semiconductors
USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
